Skip to main content


Figure 3 | Journal of Translational Medicine

Figure 3

From: Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer

Figure 3

Flow cytometry analysis of KIF20A-66 specific TCR expression in CD8+cells in case 9. Cells were stained with either KIF20A-dextramer (a) or HIV-dextramer (b) after IVS as described in Methods section. The content rates of KIF20A-dextramer positive or HIV-dextramer positive cells (red dots) in CD3+ CD4- CD8+ cells are shown above panels in red.

Back to article page